Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin
Diabetes Research and Clinical Practice — Jinnouchi H, Yoshida A, Tsuyuno H, et al. | June 11, 2021
Researchers conducted the study for analyzing the impacts of the SGLT2 inhibitor luseogliflozin on blood and urinary glucose and body weight. Thirty outpatients with type 2 diabetes were given luseogliflozin 2.5 mg once daily for 24 weeks. Urinary glucose concentration, continuous glucose monitoring values, HbA1c, fasting glucose, and body weight were all measured. Urinary glucose, subcutaneous/visceral fat mass, insulin, EPA/AA ratio, plasma free fatty acids, ghrelin, blood ketones, and plasma 1,5-anhydro-D-glucitol were all tested for correlations. The authors discovered that urinary glucose increased significantly at Week 24, whereas HbA1c and mean blood glucose decreased significantly at Week 24. Blood urea nitrogen levels were significantly higher, while urate levels were significantly lower. Although acyl ghrelin levels remained constant, des-acyl ghrelin levels increased significantly. Luseogliflozin monotherapy improved blood glucose levels, reduced body weight, and reduced insulin resistance. Luseogliflozin seems to be an effective therapy for obese diabetics.